{"id":745203,"date":"2023-04-04T10:46:02","date_gmt":"2023-04-04T14:46:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\/"},"modified":"2023-04-04T10:46:02","modified_gmt":"2023-04-04T14:46:02","slug":"tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\/","title":{"rendered":"Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>\n          <strong>Dr. Saef Izzy\u2019s data shows one-month behavioral outcomes improvement in model of intracerebral hemorrhage (hemorrhagic stroke)<\/strong>\n        <\/li>\n<li>\n          <strong>Modulation of neuroinflammation by inducing FoxP3+ Tregs appears to have beneficial effect in intracerebral hemorrhage<\/strong>\n        <\/li>\n<li>\n          <strong>Tiziana actively exploring the clinical development of foralumab into human testing for hemorrhagic stroke<\/strong><br \/>\n          \n        <\/li>\n<\/ul>\n<p>NEW YORK, April  04, 2023  (GLOBE NEWSWIRE) &#8212; Tiziana Life Sciences Ltd.\u00a0(Nasdaq: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=G3-XbUC7QD17Erf3eUhhBhgUzL_-t2vC-dMv_RvBSv6Wgwg3_ruj0wgjnDoDSLJkUZk_ovNvnbjATJcPf1f00cw6JPaJBw_fbXUHDUfrpetyeKz9JixRBw2o4yYufvfg\" rel=\"nofollow noopener\" target=\"_blank\">TLSA<\/a>) (\u201cTiziana\u201d or the \u201cCompany\u201d), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Dr. Saef Izzy will present pre-clinical data on the effects of intranasal anti-CD3 monoclonal antibody in an animal model of intracerebral hemorrhage (hemorrhagic stroke) on April 23, 2023, at 2:48 PM at Neurocritical Care Scientific Platform Session at the prestigious Annual American Academy of Neurology (AAN) conference in Boston, MA.<\/p>\n<p>Saef Izzy, M.D., MBCHB., Neurocritical Care faculty at Brigham and Women\u2019s Hospital, a founding member of Mass General Brigham healthcare system, and Assistant Professor of Neurology at Harvard Medical School, commented, \u201cI am honored to have my research<sup>1<\/sup> accepted as an oral presentation at the American Academy of Neurology annual conference. My exciting work on intranasal anti-CD3 monoclonal antibody in animal models of intracerebral hemorrhage and other acute brain injury models, show the importance of inducing regulatory T cells (Treg) in decreasing microglia activation, modulating neuroinflammatory response in the brain, and improving neurological recovery.\u201d<\/p>\n<p>Howard L. Weiner, M.D., Co-Director of the Ann Romney Center for Neurologic Diseases at Brigham and Women\u2019s Hospital and Chairman of Tiziana&#8217;s Scientific Advisory Board, stated, \u201cSaef\u2019s research demonstrates that nasal anti-CD3 increased FoxP3+ Tregs and IL-10- producing FoxP3+ Tregs in the brain. This finding aligns with our previous work in other inflammatory neurological diseases such as multiple sclerosis.\u201d<\/p>\n<p>\u201cDr. Saef Izzy\u2019s research demonstrates that intranasal foralumab, the first-ever fully human anti-CD3 monoclonal antibody, has the potential of treating a devastating condition where the vast majority of patents do not fully recover. The mechanism of action described in the recent PNAS<sup>2<\/sup> article suggests that anti-CD3 neuroimmunomodulation effects Tregs which may lead to positive motor and cognitive outcomes,\u201d stated Matthew W. Davis, M.D., RPh, Chief Medical Officer of Tiziana. \u201cBased on Dr. Izzy\u2019s research, we plan to explore further studies to develop intranasal foralumab for this devastating condition.\u201d<\/p>\n<p>______________<br \/><sup>1<\/sup><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l-T1DUmdZQIIsUIgWwyZ1RN1-6eitd9Zav0TOUiwvPMbFYtJpKE0R7qOXV4dL4x9LTEnMdigIrQtJe5sJaQY1X_-QktRuAhvW9k1o_ySp2qUkTUxw61KbH3BObGjP6YnSNQnbjO0Sla_I5507FMEfsmoGsixo5NCe8g24f4odaQabv-Zk6CahrbLjFqhkgyoy18vMzF6a0WDdG7419FGtA==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/index.mirasmart.com\/aan2023\/PDFfiles\/AAN2023-004001.html<\/a><\/p>\n<p>\n        <strong>Information About the AAN Presentation <\/strong>\n      <\/p>\n<table style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Date<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">4\/23\/2023<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Time<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">2:48 PM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Presentation (abstract) number<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">010<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Webcast link<br \/>(until May 14)<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">https:\/\/www.aan.com\/MSA\/Public\/Events\/AbstractDetails\/52974<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong>About Foralumab<\/strong>\n      <\/p>\n<p>Activated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. Intranasal foralumab Phase 2 trials are expected to start in the third quarter of 2023 in patients with non-active SPMS. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of inflammatory human diseases.<sup>2<\/sup><\/p>\n<p>______________<br \/><sup>2<\/sup><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l-T1DUmdZQIIsUIgWwyZ1e_U4s8c3lOv0vpbQu1c4FP-WMmR-xW8_Fc6Y6EbZ08BEpskANZiuZKq3n_U8Joj_R6W_Eq9TNJbaa1yAs2F5zBrHndaSV6A44m-0mbarEX_nvmm4-ARqHxtPldqT-_YlDSS_S99HoDY_cpvw9_Aj0k=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.pnas.org\/doi\/10.1073\/pnas.2220272120<\/a><\/p>\n<p>\n        <strong>About\u00a0Tiziana Life Sciences<\/strong>\n      <\/p>\n<p>Tiziana Life Sciences\u00a0is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana\u2019s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana\u2019s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana\u2019s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.<\/p>\n<p>For further inquiries:<\/p>\n<p>\n        <strong>Tiziana Life Sciences Ltd<\/strong>\n      <\/p>\n<p>Paul Spencer, Business Development and Investor Relations <br \/>+44 (0) 207 495 2379<br \/>email:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=evm0jkUH36vLn-sErAzX_hDEOGviyt-oaEj-gTfunRfVQ9v2tbQGzn9kFqcz_HmQgtsSXR7w7cthK8W5ZyFY7QAj5VfavVnI-YBWRvgCjkd3XJa5PN2pdTbmEuOJNCMIzwQT7c6yI8MuOxb8bAJuWPS9zdDJ13NBSKyt32yC9JoOVdnvH5TRXBnznrJzDDWGZp9jgQbZBBIcxYWcLFKBTdhCZq2wd03iWVdkK64lRPW0KcxtianX37oosuQ9nN_fF_D5ka8dknz46xQhRCvkgzUmZ6Gqrstdudv4BGSMcD5_souienHNik89-tdY_M1b4TSXlSwTFKWC22wh74QF8cVDHxQyIkZZmzBh_c_f4SBUZQy0SxTS1usxoZ2ah6pOCFxkQf9r7LOKm0R_2nQElF6iRsa5FhS_5qtHTBOGUVqMOoM1buWBEfd9zjWYpM9Ua42DS7N4C0b8HEwL4xPBcU9e-PZ-SpSBFd-ZjzXP3kf1ufVURcq5HrpJTQ-xrYA31l4MHlKmul9IICGYTKaatQ==\" rel=\"nofollow noopener\" target=\"_blank\"><u>info@tizianalifesciences.com<\/u><\/a><\/p>\n<p>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Irina Koffler<br \/>LifeSci Advisors, LLC<br \/>646.970.4681<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZVZaWbGfr4B6QuAFGAwmtIDUjASpEtLutcHgM6ESFjxgumdG0SC5GdxNKTHxC7ms-in5dW3NyljbYqKRow7BasD1XXVESPBrwQXmlI0596eaEfmZb6NMQgtdHY5jzvKcTLGsHJcO_Fni4ddpsmU6LD_9o0PLRl3uCl2LTlLsnH-TJ8MvUwo-P3heyciP5dbs7gn_m_LC0N0z4IcPVUP67Nhy_zFcd8Z7kJDzfDxdJ-_fr-rc8MObDTLc_Whd_VApGOJlKjRK-jN1ezubed0cxdJRIuFlp67fuEcKMEGyLKu_jd15nkD5K0F2cXTRIdQHLc_GoaudmkVgLMPQDK1Rg8uMjaq-bH8dZ3GQiTR58hSbtatYJtYjZS2BTTc5i4ZGEDHQvLfS0WhnayHxuMBiWt83j8lzH8hVqecYxwrBPkmedm3i3vUULBLwzXYG1yZ1960hInjHhV_WPEq2COrqkvScnIwvpbLJsjeuEQPPxAXP3-QsatrxmF0ITnA8p5Muu0AyFmcMrvMxWnbON31gng==\" rel=\"nofollow noopener\" target=\"_blank\"><u>ikoffler@lifesciadvisors.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTg4NyM1NTA5NTgwIzIxMjM4ODU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NjdhY2RkYjgtNDliOS00ZTM1LWFkNGQtZjljYjFmY2Y5NmNjLTExMzU0NTY=\/tiny\/Tiziana-Life-Sciences-Plc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dr. Saef Izzy\u2019s data shows one-month behavioral outcomes improvement in model of intracerebral hemorrhage (hemorrhagic stroke) Modulation of neuroinflammation by inducing FoxP3+ Tregs appears to have beneficial effect in intracerebral hemorrhage Tiziana actively exploring the clinical development of foralumab into human testing for hemorrhagic stroke NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) &#8212; Tiziana Life Sciences Ltd.\u00a0(Nasdaq: TLSA) (\u201cTiziana\u201d or the \u201cCompany\u201d), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Dr. Saef Izzy will present pre-clinical data on the effects of intranasal anti-CD3 monoclonal antibody in an animal model of intracerebral hemorrhage (hemorrhagic stroke) on April 23, 2023, at 2:48 PM at Neurocritical Care Scientific Platform Session at the prestigious Annual American &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-745203","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Dr. Saef Izzy\u2019s data shows one-month behavioral outcomes improvement in model of intracerebral hemorrhage (hemorrhagic stroke) Modulation of neuroinflammation by inducing FoxP3+ Tregs appears to have beneficial effect in intracerebral hemorrhage Tiziana actively exploring the clinical development of foralumab into human testing for hemorrhagic stroke NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) &#8212; Tiziana Life Sciences Ltd.\u00a0(Nasdaq: TLSA) (\u201cTiziana\u201d or the \u201cCompany\u201d), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Dr. Saef Izzy will present pre-clinical data on the effects of intranasal anti-CD3 monoclonal antibody in an animal model of intracerebral hemorrhage (hemorrhagic stroke) on April 23, 2023, at 2:48 PM at Neurocritical Care Scientific Platform Session at the prestigious Annual American &hellip; Continue reading &quot;Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-04T14:46:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTg4NyM1NTA5NTgwIzIxMjM4ODU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference\",\"datePublished\":\"2023-04-04T14:46:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\\\/\"},\"wordCount\":671,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMTg4NyM1NTA5NTgwIzIxMjM4ODU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\\\/\",\"name\":\"Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMTg4NyM1NTA5NTgwIzIxMjM4ODU=\",\"datePublished\":\"2023-04-04T14:46:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMTg4NyM1NTA5NTgwIzIxMjM4ODU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMTg4NyM1NTA5NTgwIzIxMjM4ODU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\/","og_locale":"en_US","og_type":"article","og_title":"Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference - Market Newsdesk","og_description":"Dr. Saef Izzy\u2019s data shows one-month behavioral outcomes improvement in model of intracerebral hemorrhage (hemorrhagic stroke) Modulation of neuroinflammation by inducing FoxP3+ Tregs appears to have beneficial effect in intracerebral hemorrhage Tiziana actively exploring the clinical development of foralumab into human testing for hemorrhagic stroke NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) &#8212; Tiziana Life Sciences Ltd.\u00a0(Nasdaq: TLSA) (\u201cTiziana\u201d or the \u201cCompany\u201d), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Dr. Saef Izzy will present pre-clinical data on the effects of intranasal anti-CD3 monoclonal antibody in an animal model of intracerebral hemorrhage (hemorrhagic stroke) on April 23, 2023, at 2:48 PM at Neurocritical Care Scientific Platform Session at the prestigious Annual American &hellip; Continue reading \"Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-04T14:46:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTg4NyM1NTA5NTgwIzIxMjM4ODU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference","datePublished":"2023-04-04T14:46:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\/"},"wordCount":671,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTg4NyM1NTA5NTgwIzIxMjM4ODU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\/","name":"Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTg4NyM1NTA5NTgwIzIxMjM4ODU=","datePublished":"2023-04-04T14:46:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTg4NyM1NTA5NTgwIzIxMjM4ODU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTg4NyM1NTA5NTgwIzIxMjM4ODU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranasal-anti-cd3-mab-in-intracerebral-hemorrhage-at-the-annual-american-academy-of-neurology-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/745203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=745203"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/745203\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=745203"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=745203"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=745203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}